RESULTS: Over a median 44-months of follow-up, 206 (42%) and 227 (46%) men progressed pathologically and therapeutically. Men who progressed had worse pathological characteristics at diagnosis (PSA, prostate volume, number of positive cores, and max percent of core involvement; p<0.05). Results of the 5 most highly correlated SNPs are presented in Table 1. After correcting for multiple analyses, one SNP (rs4464333) remained associated with pathological progres- sion (HR 5.51, 95%CI 3.01-10.1, p¼3x10 -8 ) and one SNP (rs6583016) remained borderline-associated with therapeutic progression (HR 2.30, 95%CI 1.67-3.17, p¼3x10 -7 ). Of the 11 SNPs previously studied for grade progression, rs7141529 associated with therapeutic progression (HR 1.32 95%CI 1.02-1.73, p¼0.03). CONCLUSIONS: We identified 2 novel germline genotypic variants that significantly associated with an increased risk of pro- gression in men undergoing AS. These findings may improve patient selection for, and follow-up on AS, and need validation in other cohorts. Source of Funding: Prostate Cancer Canada PD28-02 THE IMPACT OF CLINICAL CCP TESTING IN MEN WITH LOCALIZED PROSTATE CANCER FOR EXPANDING THE POPULATION OF MEN ELIGIBLE FOR ACTIVE SURVEILLANCE Behfar Ehdaie*, New York, NY; Steve Stone, Ryan Bernhisel, Salt Lake City, UT; James Eastham, New York, NY; Thomas Keane, Charlston, SC; John Davis, Houston, TX; E David Crawford, Denver, CO; Michael Brawer, Salt Lake City, UT; Daniel Lin, Seattle, WA; Peter Scardino, New York, NY INTRODUCTION AND OBJECTIVES: Active surveillance (AS) is an established treatment modality for select men with prostate cancer (PC). Eligibility criteria are based on clinicopathologic features including PSA and Gleason grade. Prior studies have validated a combined cell- cycle progression risk (CCR) score, which combines cell-cycle pro- gression (CCP) gene expression data with the Cancer of the Prostate Risk Assessment (CAPRA) score to add significant prognostic discrimination to newly diagnosed PCs. Our objective was to assess the value of the CCR score for identifying men with higher risk clinico- pathologic characteristics who qualify for AS. METHODS: Prostate biopsy samples from 17,017 men were submitted by their physicians for CCP testing (Myriad Genetic Labora- tories). The CCP score was calculated from RNA expression of 46 genes (31 CCP and 15 housekeeping genes), and combined with CAPRA to generate the CCR score. Clinicopathological data was ob- tained from physician-completed test request forms. A threshold CCR score of 0.8 was previously developed and validated in a cohort of conservatively managed men (survival data censored at 10 yrs). We evaluated the proportion of men eligible for AS based on their CCR score whose clinicopathologic criteria would traditionally disqualify them from AS: PSA>10ng/mL, Gleason grade group2 (Gleason Score 3+4), higher AUA risk. RESULTS: Overall, 66.6% of clinically tested men qualified for AS based on their CCR score. Table 1 shows that a proportion of tested men with higher risk clinicopatholic features qualified for AS based on their CCR score, including AUA intermediate (42.9%) and high (14.1%) risk as well as Gleason grade group 2 (48.8%) and Gleason grade group >2 (1-3%). In addition, 48% of men with Gleason score 6 and PSA >10 ng/mL qualified for AS. CONCLUSIONS: Clinical characteristics and Gleason grade are often used as stand-alone indicators to offer men with localized PC immediate definitive treatment rather than AS. However, our study demonstrates that a significant proportion of men who qualify for AS based on their CCR score have a range of PSA and Gleason grade prostate cancer that may not traditionally be considered for AS. This supports using CCR score to improve risk stratification in PC and identify men for AS. Source of Funding: none PD28-03 CORRELATION BETWEEN A GENOMICS TEST AND ADVERSE PATHOLOGY AFTER RADICAL PROSTATECTOMY AMONG ACTIVE SURVEILLANCE CANDIDATES Patrick Hurley*, Novi, MI; Greg Auffenberg, Ji Qi, Chris Maurino, Ann Arbor, MI; Samantha Farida, Ivi Latifi, Lansing, MI; Donald Moylan, Royal Oak, MI; Bincy Johnson, Royal Oak , MI; David Miller, Ann Arbor, MI; Kirk Wojno, Royal Oak, MI; for the Michigan Urological Surgery Improvement Collaborative, Ann Arbor, MI INTRODUCTION AND OBJECTIVES: There is growing interest among urologists in the community about the extent to which prostate cancer (CaP) genomic tests can further risk stratify men who are can- didates for active surveillance (AS). In this context, we evaluated the relationship between results from the Prolaris cell cycle progression genomics test and the frequency of adverse pathological outcomes among men treated with radical prostatectomy (RP) in a large, com- munity-based practice. METHODS: For all patients undergoing Prolaris testing in a large urology practice from 7/2013 through 4/2016, we linked test re- sults with clinical data from the Michigan Urological Surgery Improve- ment Collaborative (MUSIC) clinical registry. We then identified all men that met the published MUSIC appropriateness criteria for AS (i.e., any Gleason Score (GS) ¼6 or GS 3+4 with ¼3 positive cores and no more than 50% of any core involved), and also underwent RP as primary therapy. Genomic test results with an estimated 10-year CaP-specific mortality >3% were classified as high-risk. We then compared the frequency of adverse pathological outcomes with RP e defined as the presence of primary Gleason pattern 4 or 5 cancer and/or pathological stage T3 or T4 disease e among men with high- versus low-risk ge- nomics results. RESULTS: We identified 118 patients who were candidates for AS based on MUSIC criteria, had a Prolaris test, and primary treatment with RP. Among the entire group, 49 (42%) and 69 patients (58%) had low and high-risk genomics results, respectively. When limited to pa- tients with only GS 6 cancer on diagnostic biopsy (n¼26), only 4 men (15%) had high-risk Prolaris results. For the entire cohort (Figure 1a), patients with high-risk genomic results were more likely to have path- ological stage T3 or T4 tumors (36.2% vs 12.2%, p ¼0.004). Among the Vol. 197, No. 4S, Supplement, Saturday, May 13, 2017 THE JOURNAL OF UROLOGY â e517